N@N

Bio-Rad Introduces its IH 1000, an Automated Blood Screening System

^{Published on 2010-06-30 13:30:44 - Market Wire}
 

HERCULES, CA--(Marketwire - June 30, 2010) - Bio-Rad Laboratories, Inc. (NYSE: [ BIO ]) and (NYSE: [ BIO.B ]), a multinational manufacturer and distributor of life science research and clinical diagnostics products, today announced the launch of its IH 1000 blood screening system.

The IH 1000 is a fully-automated, high-throughput system designed for the blood transfusion laboratory utilizing the industry accepted gold standard ID-System gel card technology. The new system offers full automation, integrated QC and validation, intuitive software, and walk-away convenience for blood banking laboratories.

"With the introduction of IH 1000, Bio-Rad offers a compelling new system designed specifically for the transfusion laboratory," said John Goetz, Bio-Rad Vice President and Group Manager Clinical Diagnostics. "Our customers who have already worked with the IH 1000 during our testing phase have said the system delivers the highest level of automation as well as improved workflow advantages -- without sacrificing the quality of the result."

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: [ BIO ]) and (NYSE: [ BIO.B ]) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,900 people globally and had revenues of nearly $1.8 billion in 2009. For more information, visit [ www.bio-rad.com ].

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.